Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials

Antonio M Risitano, Bing Han, Austin G. Kulasekararaj, Yasutaka Ueda, Phillip Scheinberg, Carlos de Castro, Jaroslaw Maciejewski, Josefin Snellman, Olivier Somenzi, Randall Winnette, Samopriyo Maitra, Shujie Li, Marion Dahlke, Regis Peffault De Latour

Blood (2024) 144 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2024-203532

Published: 2024

Journal Articles

The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial

Regis Peffault De Latour, Austin G. Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos de Castro, Samopriyo Maitra, Philippe Ferber, Marion Dahlke, Antonio M Risitano

Blood (2024) 144 (Supplement 1): 4087.

https://doi.org/10.1182/blood-2024-200763

Published: 2024

Journal Articles

Patient Experience Interviews with a Novel Treatment Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Carlos De Castro, Phillip Scheinberg, Bing Han, Susan Vallow, Georgina Bermann, Marion Dahlke, Zhixin Wang, Rakesh Kumar, Gavin Dickie, Caitlyn Lowe, Kaelyn Rupinski, Amber Nieves, Regis Peffault De Latour

Blood (2023) 142 (Supplement 1): 7339.

https://doi.org/10.1182/blood-2023-186840

Published: 2023

Journal Articles

Categorization of Hematological Responses to Oral Iptacopan Monotherapy in Anti-C5-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia in the Phase III APPLY-PNH Trial and Complement Inhibitor-Naïve Patients in the Phase III APPOINT-PNH Trial

Antonio M Risitano, Bing Han, Austin Kulasekararaj, Yasutaka Ueda, Phillip Scheinberg, Carlos de Castro, Jaroslaw P. Maciejewski, Josefin Snellman, Ranjan Tiwari, Marion Dahlke, Régis Peffault de Latour

Blood (2023) 142 (Supplement 1): 4084.

https://doi.org/10.1182/blood-2023-180866

Published: 2023

Journal Articles

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Blood (2023) 142 (Supplement 1): 571.

https://doi.org/10.1182/blood-2023-180780

Published: 2023

Journal Articles

Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant

Cindy M. Pabon, MD, Zhiguo Li, PhD, Therese Hennig, PA, Carlos De Castro, Jadee Neff, MD PhD, Mitchell E. Horwitz, MD, Thomas W. Leblanc, Gwynn D. Long, MD, Richard D. Lopez, MD, Anthony D. Sung, MD, Nelson J. Chao, MD MBA, Cristina Gasparetto, MD, Stefanie Sarantopoulos, MD PhD, Donna B. Adams, NP, Harry P. Erba, MD PhD, David A Rizzieri, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-133901

Published: 2020

Journal Articles

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

Dale J. Christensen, PhD, Jessica Oddo, B.S., Karen Bond, Alicia Volkheimer, M.S., Youwei Chen, MD, Evan Davis, BS, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos de Castro, III, MD, Joseph O. Moore, MD, Michael P Vitek, PhD, J. Brice Weinberg, MD

Blood (2010) 116 (21): 4190.

https://doi.org/10.1182/blood.V116.21.4190.4190

Published: 2010

Journal Articles

Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Robert A Brodsky, MD, Carlos de Castro, III, MD, Hubert Schrezenmeier, MD, Professor, Antonio M. Risitano, MD, PhD, Joerg Schubert, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Ulrich Duehrsen, MD, Lucio Luzzatto, MD, FRCP, FRCPath, Petra Muus, MD, PhD, Jeffrey Szer, BMedSc, MBBS, FRACP, Gérard Socié, MD, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 4237.

https://doi.org/10.1182/blood.V116.21.4237.4237

Published: 2010

Journal Articles

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.

Cristina Gasparetto, MD, Jon P Gockerman, Louis F Diehl, MD, Carlos de Castro, III, MD, Joseph O Moore, Gwynn D Long, Mitchell Horwitz, MD, John Chute, MD, Keith M Sullivan, MD, Rachel Neuwirth, Patricia H Davis, Linda M. Sutton, Russell D Anderson, Nelson Chao, David A. Rizzieri, MD

Blood (2008) 112 (11): 3325.

https://doi.org/10.1182/blood.V112.11.3325.3325

Published: 2008

Journal Articles

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky, Neal S. Young, Elisabetta Antonioli, Antonio M. Risitano, Hubert Schrezenmeier, Jörg Schubert, Anna Gaya, Luke Coyle, Carlos de Castro, Chieh-Lin Fu, Jaroslaw P. Maciejewski, Monica Bessler, Henk-André Kroon, Russell P. Rother, Peter Hillmen

Blood (2008) 111 (4): 1840–1847.

https://doi.org/10.1182/blood-2007-06-094136

Published: 2008

Journal Articles

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Neal S. Young, MD, Elisabetta Antonioli, MD, Bruno Rotoli, MD, Hubert Schrezenmeier, MD, Jörg Schubert, MD, Alvaro Urbano-Ispizua, MD, Luke Coyle, MD, Carlos de Castro, MD, Chieh-Lin Fu, MD, Jaroslaw P. Maciejewski, MD, PhD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Peter Hillmen, MB PhD

Blood (2006) 108 (11): 971.

https://doi.org/10.1182/blood.V108.11.971.971

Published: 2006

Journal Articles

Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.

Debashish Misra, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis Diehl, MD, Carlos de Castro, MD, Yiping Yang, MD, Cristina Gasparetto, MD, Amy Abernathy, MD, Mitchell Horwitz, MD, Gwynn D. Long, MD, John Chute, MD, Bercedis Peterson, Ph.D, Nelson J. Chao, MD, David A. Rizzieri, MD

Blood (2005) 106 (11): 4623.

https://doi.org/10.1182/blood.V106.11.4623.4623

Published: 2005

Journal Articles

Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.

Sam O. Wanko, MD, Jon P. Gockerman, M.D, Joseph O. Moore, M.D, Carlos de Castro, M.D, Louis Diehl, M.D, Robert Pronitz, M.D, Cristina Gasparetto, M.D, John Chute, M.D, Mitchell Horwitz, M.D, Ashley Morris, Pharm.D, Francis Ali-Osman, PhD, Arati Rao, M.D, Donna Niedzweicki, PhD, Gwynn D. Long, M.D, Nelson J. Chao, M.D, David A. Rizzieri, M.D

Blood (2005) 106 (11): 5501.

https://doi.org/10.1182/blood.V106.11.5501.5501

Published: 2005

Journal Articles

The Use of DT388-IL3 Fusion Protein in Patients with Refractory Acute Myeloid Leukemia(AML).

Debashish Misra, M.D., Arthur Frankel, M.D., Philip Hall, Pharm.D., Tie Fu Liu, M.D., Jennifer Black, R.N., Joseph O. Moore, M.D., Carlos de Castro, M.D., Jon P. Gockerman, M.D., Cristina Gasparetto, M.D., Mitchell Horwitz, M.D., Patricia H. Davis, R.N., Nelson J. Chao, M.D., David A. Rizzieri, M.D.

Blood (2004) 104 (11): 4513.

https://doi.org/10.1182/blood.V104.11.4513.4513

Published: 2004

Journal Articles

First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).

Hussain Saba, Craig Rosenfeld, Jean-Pierre Issa, John DiPersio, Azra Raza, Virginia Klimek, James Slack, Carlos de Castro, Karl Mettinger, Hagop Kantarjian

Blood (2004) 104 (11): 67.

https://doi.org/10.1182/blood.V104.11.67.67

Published: 2004

NARROW

Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials

The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial

Patient Experience Interviews with a Novel Treatment Iptacopan for Paroxysmal Nocturnal Hemoglobinuria

Categorization of Hematological Responses to Oral Iptacopan Monotherapy in Anti-C5-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia in the Phase III APPLY-PNH Trial and Complement Inhibitor-Naïve Patients in the Phase III APPOINT-PNH Trial

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial

Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant

Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas

Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Interim Shepherd Phase III Clinical Study.

Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.

Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.

The Use of DT388-IL3 Fusion Protein in Patients with Refractory Acute Myeloid Leukemia(AML).

First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only